Qiagen Aims for Over 30% Operating Margin with 2025 EPS Forecast at $2.35

Qiagen (NYSE: QGEN), a frontrunner in molecular diagnostics, has updated its earnings projection for 2025, citing robust sales growth and favorable market conditions. This revision comes on the heels of preliminary first-quarter results that exceeded expectations.

Qiagen Announces Upward Revision to Projected Earnings for 2025

Qiagen, renowned for its work in molecular diagnostics and sample preparation, has announced an upward revision to its projected earnings for 2025. The company’s adjusted diluted earnings per share are now expected to reach approximately $2.35, up from a previous forecast of $2.28.

This positive adjustment is attributed to strong sales figures in the first quarter and ongoing positive business trends. Preliminary results for the first quarter reveal an adjusted earnings per share of at least 55 cents, surpassing the consensus estimate of 49 cents. In addition, Qiagen’s net sales at constant exchange rates for the quarter are reported at $483 million.

Despite foreseen challenges from new U.S. import tariffs, the company is focused on improving its adjusted operating income margin to over 30% for the year.

Join our Telegram group and never miss a breaking digital asset story.

QGEN Stock Brief

Qiagen’s stock has experienced a range of movements in recent trading sessions. The stock’s previous close was at $40.37, while it opened at $39.61. Throughout the day, it reached a low of $38.13 and a high of $39.74, and closed at $38.26. As of April 7, 2025, at 07:31 EDT the premarket price was noted at $39.32. Over the past 52 weeks, the stock has seen a low of $37.63 and a high of $47.93.

Key metrics for Qiagen include a market capitalization of $8.27 billion, a trailing P/E ratio of 100.68, and a forward P/E ratio of 16.71. With a book value of $16.51 and a price-to-book ratio of 2.32, the company’s financial health appears solid.

The debt-to-equity ratio stands at 42.4, and the trailing EPS is $0.38, with a forward EPS of $2.29. Investor sentiment remains positive, with a recommendation key of “Buy” and a recommendation mean of 2.11. The target price range for the stock is between $42.00 and $55.00, with a mean target price of $49.80.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.